Potential drugs for elimination of acute lymphatic leukemia cells from autologous bone marrow.
Five drugs, selected because of minimal in vivo myelotoxicity, have been investigated for inhibition of the growth of three acute lymphatic leukemia-derived cell lines. Granulocyte-macrophage colony-forming units (GM-CFU) inhibition with these five drugs after 60-min incubation was first established. Drug concentrations giving up to 90% kill of GM-CFU were then used. Spirogermanium and L-asparaginase did not have an effect on any of the three cell lines under the culture conditions tested, while 4-hydroperoxycyclophosphamide (4-HC) and vincristine inhibited the growth of all three cell lines tested, and bleomycin inhibited the growth of two cell lines. In addition to 4-HC, bleomycin and vincristine should be considered as possible agents in eliminating leukemic cells from autologous marrow grafts. These drugs also deserve further investigation in clonal systems.
D000970:Antineoplastic Agents / Q000633:toxicity*; D001215:Asparaginase / Q000633:toxicity; D001761:Bleomycin / Q000633:toxicity; D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology; D001854:Bone Marrow Cells; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D003520:Cyclophosphamide / Q000031:analogs & derivatives / Q000633:toxicity; D005857:Germanium / Q000633:toxicity; D006412:Hematopoietic Stem Cells / Q000166:cytology* / Q000187:drug effects; D006801:Humans; D007700:Kinetics; D007945:Leukemia, Lymphoid / Q000473:pathology*; D009942:Organometallic Compounds; D013141:Spiro Compounds / Q000633:toxicity; D014750:Vincristine / Q000633:toxicity
D000970:Antineoplastic Agents; D009942:Organometallic Compounds; D013141:Spiro Compounds; D005857:Germanium; D001761:Bleomycin; C026818:spirogermanium; D014750:Vincristine; D003520:Cyclophosphamide; D001215:Asparaginase; C011272:perfosfamide